NYSE:MTNB
Matinas Biopharma Holdings Inc Stock News
$0.290
+0.0042 (+1.47%)
At Close: Mar 27, 2024
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021
07:00am, Tuesday, 27'th Jul 2021
BEDMINSTER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of c
Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts
12:16pm, Sunday, 13'th Jun 2021
Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks,
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerome Jabbour on Q1 2021 Results - Earnings Call Transcript
12:21pm, Monday, 10'th May 2021
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerome Jabbour on Q1 2021 Results - Earnings Call Transcript
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates
08:16am, Monday, 10'th May 2021
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -67.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for
Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights
06:30am, Monday, 10'th May 2021
– Enrollment continues in second cohort of EnACT study of MAT2203 (oral amphotericin b) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data fro
Matinas BioPharma Hldgs's Earnings: A Preview
10:09am, Friday, 07'th May 2021
Matinas BioPharma Hldgs (AMEX:MTNB) announces its next round of earnings this Monday, May 10. Here is Benzinga's everything-that-matters guide for this Monday's Q1 earnings announcement.
Matinas BioPharma to Participate in 7th Annual Truist Securities Life Sciences Summit
07:30am, Wednesday, 28'th Apr 2021
BEDMINSTER, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participat
Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2021 Financial and Operational Results on May 10, 2021
07:30am, Tuesday, 27'th Apr 2021
BEDMINSTER, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of
Matinas BioPharma to Present at the Needham Healthcare Conference
07:30am, Thursday, 08'th Apr 2021
BEDMINSTER, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a
Matinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerry Jabbour on Q4 2020 Results - Earnings Call Transcript
01:13pm, Monday, 29'th Mar 2021
Matinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerry Jabbour on Q4 2020 Results - Earnings Call Transcript
Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
06:30am, Monday, 29'th Mar 2021
– Matinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics –
Matinas BioPharma to Present at the Barclays Global Healthcare Conference
07:30am, Monday, 01'st Mar 2021
BEDMINSTER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a
Why Matinas BioPharma Stock Crashed Today
04:28pm, Monday, 01'st Feb 2021
The company reported disappointing clinical results.
Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®
06:00am, Monday, 01'st Feb 2021
– LYPDISO ™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa ® –
Matinas: Learning From Amarin's Mistakes
08:05pm, Wednesday, 06'th Jan 2021
Matinas has an OM3 drug that has demonstrated a superior profile to Amarin's Vascepa. It has a platform and, unlike Amarin, a diverse pipeline.